{"id":981,"date":"2018-06-21T12:22:39","date_gmt":"2018-06-21T11:22:39","guid":{"rendered":"http:\/\/www.mub.eps.manchester.ac.uk\/in-abstract\/?p=981"},"modified":"2018-09-03T11:42:35","modified_gmt":"2018-09-03T10:42:35","slug":"arylation-of-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.mub.eps.manchester.ac.uk\/in-abstract\/arylation-of-pharmaceuticals\/","title":{"rendered":"Cyclometallated ruthenium catalyst enables late-stage directed arylation of pharmaceuticals"},"content":{"rendered":"

New class of ruthenium catalysts allows late-stage arylation of drugs<\/strong><\/p>\n

Most drugs and other biologically active compounds incorporate a large number of polar functional groups, which are responsible for the observed activity. However, the presence of these polar groups increase difficulty for chemists to modify these compounds as often transition metal catalyst will be incompatible with those functionalities.<\/p>\n

Chemists at the University of Manchester have uncovered new mechanistic insights on the workings of ruthenium-catalysed C\u2012H arylations. This discovery has led to the design of a new class of ruthenium catalysts that present extremely high reactivity, when compared to current state-of-the-art catalysts, on C\u2012H arylation. These catalysts maintain their high reactivity under very mild conditions (e.g. room temperature), while displaying exquisite selectivity and efficiency, making them particularly suitable for the modification of highly functionalized delicate molecules such as drugs compounds. These ruthenium catalysts provide chemists with a tool to install aromatic groups at desired positions of complex molecules, opening the door to the exploration of new chemical space that would otherwise be impractical to access.<\/p>\n

<\/p>\n